Halozyme Therapeutics, Inc (HALO)
Orange 📈 GrowthHealth Care · As of 17 July 2026
Price chart — 52 weeks
OakBag’s model puts the fair value of Halozyme Therapeutics, Inc (HALO) at about $101.68, against a recent price of $77.81 — a margin of safety of +23%. On that basis the traffic light is set so it looks fairly valued. The estimate blends up to 4 independent valuation methods and is benchmarked against other Health Care names. It is a model estimate for research, not a price target or a recommendation.
Fair value vs. price
- Current price
- $77.81
- Estimated fair value
- $101.68
- Margin of safety
- +23%
- Growth fair value
- $141.00
- Margin of safety (growth)
- +45%
How the fair value is built
Why not green?
- It looks cheap largely because of its high quality. Stripping the quality premium out, the margin of safety is only 5% — below the buy bar (quality is already rewarded in the score).
Knock-out safety checks passed
- Bankruptcy risk (Altman Z″)
- Negative equity
- Excessive leverage
- Illiquid
- Penny / micro-cap
- Stale fundamentals
- Piotroski F-score
- 5 / 9
- Altman Z-score
- 6.34
- Beneish M-score
- -2.48
Quality & factor profile
Retail attention
- Attention
- 59 / 100
- Mentions today
- 1
- Spike vs. 24h ago
- 1×
See the full analysis
Create a free OakBag account to unlock every valuation method, price history, watchlists and email alerts for HALO and 1,850+ other stocks.
No credit card · just an email
Frequently asked questions
Is Halozyme Therapeutics (HALO) undervalued?
On OakBag’s model, Halozyme Therapeutics, Inc looks fairly valued: the estimated fair value is $101.68 versus a recent price of $77.81, a margin of safety of +23%. This is a model estimate, not investment advice.
What is HALO’s fair value estimate?
OakBag estimates Halozyme Therapeutics, Inc’s fair value at about $101.68, blending up to 4 methods — peer P/E, price-to-book, peer EV/EBITDA, a machine-learning valuation and a cash-flow DCF — clipped to a sensible band and taken at the median.
What is margin of safety?
Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. Here it is +23%. A positive number means the model sees the stock as cheap; OakBag only turns a stock green above +15%.
Does a green verdict mean I should buy HALO?
No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.
Other Health Care stocks
An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.